CD8A and neoplasm: In this study, our group found that the small-molecule tyrosine kinase inhibitor DCC-2036 could induce repolarization of TAMs from M2 to M1 type and enhance anti-tumor CD8<sup>+</sup> T cell immunity in TNBC.